Literature DB >> 35924916

EUCAST-Obtained Olorofim MICs against Aspergillus and Scedosporium Species and Lomentospora prolificans Showed High Agreements between Visual Inspection and Spectrophotometric Readings.

Pilar Escribano1,2, Ana Gómez1,2, Elena Reigadas1,2,3,4, Patricia Muñoz1,2,3,4, Jesús Guinea1,2,3.   

Abstract

Previous studies show high agreement between MIC spectrophotometric readings and visual inspection of azoles and amphotericin B against Aspergillus fumigatus isolates. Here, we tested and compared the in vitro activity of a novel antifungal, olorofim, against Aspergillus spp., Scedosporium spp., and Lomentospora prolificans by visual inspection and spectrophotometric readings. Clinical isolates of Aspergillus (n = 686) and Scedosporium (n = 36) spp. and L. prolificans (n = 13) were tested. Olorofim MICs were evaluated-following the EUCAST E.Def 9.4 procedure-by visual inspection or spectrophotometric readings (combinations of either ≥90% or ≥95% fungal growth inhibition endpoints compared to drug-free control endpoints and different wavelengths [405 nm, 450 nm, 492 nm, 540 nm, and 620 nm]). We observed high in vitro activity of olorofim against all tested Aspergillus spp. (MICs up to 0.06 mg/L), except for A. calidoustus, and against L. prolificans and Scedosporium spp. (MICs up to 0.125 mg/L). The combination of ≥90% fungal growth inhibition endpoints at wavelengths of ≥492 nm resulted in high essential agreements with A. fumigatus and lesser agreement with non-fumigatus Aspergillus, Scedosporium spp., and L. prolificans, although the number of isolates studied was low. This single-center study shows high agreement among olorofim MICs against A. fumigatus by visual inspection and spectrophotometric readings (≥90% fungal growth inhibition endpoints and wavelengths of ≥492 nm) and encouraging results against non-fumigatus Aspergillus spp., Scedosporium spp., and L. prolificans.

Entities:  

Keywords:  Aspergillus; EUCAST; Lomentospora prolificans; Scedosporium; olorofim; spectrophotometric reading

Mesh:

Substances:

Year:  2022        PMID: 35924916      PMCID: PMC9487512          DOI: 10.1128/aac.00849-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  29 in total

1.  In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.

Authors:  Russell E Lewis; Nathan P Wiederhold; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies.

Authors:  Olga Rivero-Menendez; Manuel Cuenca-Estrella; Ana Alastruey-Izquierdo
Journal:  J Antimicrob Chemother       Date:  2019-06-01       Impact factor: 5.790

3.  Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus.

Authors:  J Meletiadis; K Leth Mortensen; P E Verweij; J W Mouton; M C Arendrup
Journal:  Clin Microbiol Infect       Date:  2016-10-25       Impact factor: 8.067

4.  EUCAST Determination of Olorofim (F901318) Susceptibility of Mold Species, Method Validation, and MICs.

Authors:  Karin Meinike Jørgensen; Karen M T Astvad; Rasmus Krøger Hare; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

5.  Spectrophotometric azole and amphotericin B MIC readings against Aspergillus fumigatus sensu lato using the EUCAST 9.3.2 methodology. Are ≥90 and ≥95% fungal growth inhibition endpoints equally suitable?

Authors:  Julia Serrano-Lobo; Ana Gómez; Patricia Muñoz; Pilar Escribano; Jesús Guinea
Journal:  Med Mycol       Date:  2021-12-08       Impact factor: 4.076

6.  Ribosomal DNA internal transcribed spacers are highly divergent in the phytopathogenic ascomycete Fusarium sambucinum (Gibberella pulicaris).

Authors:  K O'Donnell
Journal:  Curr Genet       Date:  1992-09       Impact factor: 3.886

7.  Invasive aspergillosis due to Aspergillus cryptic species: a prospective multicenter study.

Authors:  Sebastien Imbert; Sophie Cassaing; Christine Bonnal; Anne-Cecile Normand; Frederic Gabriel; Damien Costa; Marion Blaize; Laurence Lachaud; Lilia Hasseine; Lise Kristensen; Juliette Guitard; Christine Schuttler; Helene Raberin; Sophie Brun; Marijke Hendrickx; Renaud Piarroux; Arnaud Fekkar
Journal:  Mycoses       Date:  2021-06-28       Impact factor: 4.377

8.  In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.

Authors:  Olga Rivero-Menendez; Manuel Cuenca-Estrella; Ana Alastruey-Izquierdo
Journal:  J Antimicrob Chemother       Date:  2020-12-01       Impact factor: 5.790

Review 9.  Antifungal susceptibility profile of cryptic species of Aspergillus.

Authors:  Ana Alastruey-Izquierdo; Laura Alcazar-Fuoli; Manuel Cuenca-Estrella
Journal:  Mycopathologia       Date:  2014-06-28       Impact factor: 2.574

10.  Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance.

Authors:  Jochem B Buil; Jason D Oliver; Derek Law; Tim Baltussen; Jan Zoll; Margriet W J Hokken; Marlou Tehupeiory-Kooreman; Willem J G Melchers; Mike Birch; Paul E Verweij
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.